160 related articles for article (PubMed ID: 23095879)
1. Combination of irinotecan (CPT-11) and nedaplatin (NDP) for recurrent patients with uterine cervical cancer.
Ohara T; Kobayashi Y; Yoshida A; Yoshioka N; Yahagi N; Kondo H; Tozawa A; Kiguchi K; Suzuki N
Int J Clin Oncol; 2013 Dec; 18(6):1102-6. PubMed ID: 23095879
[TBL] [Abstract][Full Text] [Related]
2. Phase I study of combination chemotherapy using irinotecan hydrochloride and nedaplatin for advanced or recurrent cervical cancer.
Machida S; Ohwada M; Fujiwara H; Konno R; Takano M; Kita T; Kikuchi Y; Komiyama S; Mikami M; Suzuki M
Oncology; 2003; 65(2):102-7. PubMed ID: 12931014
[TBL] [Abstract][Full Text] [Related]
3. Phase II clinical study of irinotecan and cisplatin as first-line chemotherapy in metastatic or recurrent cervical cancer.
Chitapanarux I; Tonusin A; Sukthomya V; Charuchinda C; Pukanhapan N; Lorvidhaya V
Gynecol Oncol; 2003 Jun; 89(3):402-7. PubMed ID: 12798702
[TBL] [Abstract][Full Text] [Related]
4. Phase II study of neoadjuvant chemotherapy with irinotecan hydrochloride and nedaplatin followed by radical hysterectomy for bulky stage Ib2 to IIb, cervical squamous cell carcinoma: Japanese Gynecologic Oncology Group study (JGOG 1065).
Yamaguchi S; Nishimura R; Yaegashi N; Kiguchi K; Sugiyama T; Kita T; Kubushiro K; Kokawa K; Hiura M; Mizutani K; Yamamoto K; Takizawa K
Oncol Rep; 2012 Aug; 28(2):487-93. PubMed ID: 22614251
[TBL] [Abstract][Full Text] [Related]
5. Clinical efficacy of neoadjuvant chemotherapy with irinotecan (CPT-11) and nedaplatin followed by radical hysterectomy for locally advanced cervical cancer.
Abou-Taleb HA; Koshiyama M; Matsumura N; Baba T; Yamaguchi K; Hamanishi J; Abiko K; Yamanoi K; Murakami R; Horikawa N; Taha AA; Kitamura S; Konishi I
J Int Med Res; 2016 Apr; 44(2):346-56. PubMed ID: 26831404
[TBL] [Abstract][Full Text] [Related]
6. Neoadjuvant chemotherapy followed by radical hysterectomy plus postoperative chemotherapy but no radiotherapy for Stage IB2-IIB cervical cancer--irinotecan and platinum chemotherapy.
Matsumura M; Takeshima N; Ota T; Omatsu K; Sakamoto K; Kawamata Y; Umayahara K; Tanaka H; Akiyama F; Takizawa K
Gynecol Oncol; 2010 Nov; 119(2):212-6. PubMed ID: 20709382
[TBL] [Abstract][Full Text] [Related]
7. Phase I-II study of irinotecan (CPT-11) plus nedaplatin (254-S) with recombinant human granulocyte colony-stimulating factor support in patients with advanced or recurrent cervical cancer.
Tsuda H; Hashiguchi Y; Nishimura S; Miyama M; Nakata S; Kawamura N; Negoro S
Br J Cancer; 2004 Sep; 91(6):1032-7. PubMed ID: 15292935
[TBL] [Abstract][Full Text] [Related]
8. Recurrent cervical cancer in a patient who was compound heterozygous for UGT1A1*6 and UGT1A1*28 presenting with serious adverse events during irinotecan hydrochloride/nedaplatin therapy.
Takatori E; Shoji T; Miura Y; Takeuchi S; Yoshizaki A; Sugiyama T
J Obstet Gynaecol Res; 2013 Aug; 39(8):1354-8. PubMed ID: 23800356
[TBL] [Abstract][Full Text] [Related]
9. Phase I study of combination chemotherapy with irinotecan hydrochloride and nedaplatin for cervical squamous cell carcinoma: Japanese gynecologic oncology group study.
Yamamoto K; Kokawa K; Umesaki N; Nishimura R; Hasegawa K; Konishi I; Saji F; Nishida M; Noguchi H; Takizawa K
Oncol Rep; 2009 Apr; 21(4):1005-9. PubMed ID: 19288001
[TBL] [Abstract][Full Text] [Related]
10. [Combined irinotecan (CPT-11) and nedaplatin (254-S) therapy for advanced and/or recurrent cervical cancer].
Hiruma R; Kamide T; Anzai N; Matsumoto R; Kotake Y; Wachi T; Shinozaki H; Tada A; Kamiya N; Sasaki H
Gan To Kagaku Ryoho; 2008 Apr; 35(4):607-10. PubMed ID: 18408429
[TBL] [Abstract][Full Text] [Related]
11. Bimonthly chemotherapy with oxaliplatin, irinotecan, infusional 5-fluorouracil/folinic acid in patients with metastatic colorectal cancer pretreated with irinotecan- or oxaliplatin-based chemotherapy.
Nobili S; Checcacci D; Filippelli F; Del Buono S; Mazzocchi V; Mazzei T; Mini E
J Chemother; 2008 Oct; 20(5):622-31. PubMed ID: 19028627
[TBL] [Abstract][Full Text] [Related]
12. A phase II study of irinotecan (CPT-11) in patients with advanced squamous cell carcinoma of the cervix.
Irvin WP; Price FV; Bailey H; Gelder M; Rosenbluth R; Durivage HJ; Potkul RK
Cancer; 1998 Jan; 82(2):328-33. PubMed ID: 9445190
[TBL] [Abstract][Full Text] [Related]
13. Phase II trial of paclitaxel and nedaplatin in patients with advanced/recurrent uterine cervical cancer: a Kansai Clinical Oncology Group study.
Takekuma M; Hirashima Y; Ito K; Tsubamoto H; Tabata T; Arakawa A; Itani Y; Furukawa N; Murakoshi H; Takeuchi S
Gynecol Oncol; 2012 Sep; 126(3):341-5. PubMed ID: 22609108
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of combination chemotherapy using irinotecan and nedaplatin for patients with recurrent and refractory endometrial carcinomas: preliminary analysis and literature review.
Miyamoto M; Takano M; Kuwahara M; Soyama H; Kato K; Matuura H; Sakamoto T; Takasaki K; Aoyama T; Yoshikawa T; Furuya K
Cancer Chemother Pharmacol; 2018 Jan; 81(1):111-117. PubMed ID: 29124328
[TBL] [Abstract][Full Text] [Related]
15. Combination therapy with irinotecan and cisplatin as neoadjuvant chemotherapy in locally advanced cervical cancer.
Sugiyama T; Nishida T; Kumagai S; Nishio S; Fujiyoshi K; Okura N; Yakushiji M; Hiura M; Umesaki N
Br J Cancer; 1999 Sep; 81(1):95-8. PubMed ID: 10487618
[TBL] [Abstract][Full Text] [Related]
16. [Results of neoadjuvant chemotherapy using tri-weekly CDDP/CPT-11 for locally advanced cervical cancer].
Shoji T; Takatori E; Murai M; Hatayama S; Omi H; Kagabu M; Honda T; Kumagai S; Morohara Y; Yoshizaki A; Sugiyama T; Kaido Y; Miura F; Satoh A
Gan To Kagaku Ryoho; 2010 Apr; 37(4):643-8. PubMed ID: 20414019
[TBL] [Abstract][Full Text] [Related]
17. Phase II study of irinotecan and cisplatin as first-line chemotherapy in advanced or recurrent cervical cancer.
Sugiyama T; Yakushiji M; Noda K; Ikeda M; Kudoh R; Yajima A; Tomoda Y; Terashima Y; Takeuchi S; Hiura M; Saji F; Takahashi T; Umesaki N; Sato S; Hatae M; Ohashi Y
Oncology; 2000; 58(1):31-7. PubMed ID: 10644938
[TBL] [Abstract][Full Text] [Related]
18. A modified shortened administration schedule for neoadjuvant chemotherapy with irinotecan and cisplatin in locally advanced cervical cancer.
Ren Y; Li Y; Liu J
Int J Gynecol Cancer; 2011 May; 21(4):685-9. PubMed ID: 21543932
[TBL] [Abstract][Full Text] [Related]
19. Comparison of combination chemotherapy with irinotecan and cisplatin regimen administered every 2 or 4 weeks in pretreated patients with unresectable or recurrent gastric cancer: retrospective analysis.
Sakamoto T; Yasui H; Boku N; Onozawa Y; Hironaka S; Fukutomi A; Yamazaki K; Taku K; Machida N; Todaka A; Tomita H; Tsushima T; Taniguchi H; Hamauchi S
Int J Clin Oncol; 2010 Jun; 15(3):287-93. PubMed ID: 20217447
[TBL] [Abstract][Full Text] [Related]
20. A phase 2 study of nanoparticle albumin-bound paclitaxel plus nedaplatin for patients with advanced, recurrent, or metastatic cervical carcinoma.
Li Y; Zeng J; Huang M; An J; Bai P; Wu L; Zhang R
Cancer; 2017 Feb; 123(3):420-425. PubMed ID: 27696395
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
